Yep, I can never quite get over the line with this company. It always seems to me that, as a world leader in their field, they should perform better than they ever manage.
They fully expense their R and D and that runs at somewhere between 12% and 14% each year which is quite high.
The thing is that their revenue over recent times has averaged increases of less than that.
Their products are expensive - perhaps the uncertainty around the world has caused customers to hold back more than normal.
Ann: Cochlear provides update to FY25 earnings guidance, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$312.83 |
Change
-1.180(0.38%) |
Mkt cap ! $20.45B | |||
| Open | High | Low | Value | Volume |
| $314.04 | $316.34 | $312.83 | $32.53M | 103.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $312.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $314.51 | 72 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |